

POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**POWER OF ATTORNEY BY ASSIGNEE  
AND EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71  
WITH STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The undersigned assignee of the patents and patent applications listed on Attachment A, hereby appoints Practitioners of Jones Day associated with Customer Number 20583, which mailing address is Jones Day, 222 East 41st Street, New York, New York 10017, as its attorneys to prosecute these applications and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71.

Please direct all correspondence for this application to Customer no. 20583.

**Statement Under 37 C.F.R. 3.73(b)**

L'UNIVERSITÉ MONTPELLIER II states that it is:

the assignee of the entire right, title, and interest; or  
 an assignee of less than the entire right, title and interest.

in the patent applications/patent identified above by virtue of:

An assignment agreement dated March 4, 2009. The assignment agreement was recorded in the United States Patent and Trademark Office on May 6, 2009 at Reel 022644, Frame 0923, or for which a copy thereof is attached.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

**ASSIGNEE: L'UNIVERSITÉ MONTPELLIER II**

Date:

26/05/2009

Signature:

Typed Name: DANIELLE HÉRIN

Position>Title: PRESIDENT



**Attachment A**

Joint Dkt. No./M	Docket No.	Serial No.	Serial No.	Filed	Title
Joint Dkt. No./M	Docket No.	Serial No.	Serial No.	Filed	Title
417451-888016	11874-016-288	1017 US PROV	Goselin, G. Sommadossi, J.-P. Munca, A. Pietra, C. Bacaria-Prod. S. Duhon, D. LaColla, P.	60/932,251	6/26/02 " and 3' Nucleoside Prodrugs for Treating Hepatitis C Virus
417451-999016	11874-016-299	1017 US	11874-015-388 11874-016-488 11874-130-488	16/669,298	6/27/03 " and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999047	11874-047-599	1017 US CON 1	CON of Goselin, G. Storer, R. LaColla, P. Sommadossi, J.-P.	11/005,471	12/6/04 " and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999048	11874-048-599	1017 US CON 2	CON of Goselin, G. Storer, R. LaColla, P. Sommadossi, J.-P.	11/005,442	12/6/04 " and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999049	11874-049-599	1017 US CON 3	CON of Goselin, G. Storer, R. LaColla, P. Sommadossi, J.-P.	11/005,466	12/6/04 " and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999050	11874-050-599	1017 US CON 4	CON of Goselin, G. Storer, R. LaColla, P. Sommadossi, J.-P.	11/005,440	12/6/04 " and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999051	11874-051-599	1017 US CON 5	CON of Goselin, G. Storer, R. LaColla, A. Sommadossi, J.-P.	11/005,443	12/6/04 " and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999052	11874-052-599	1017 US CON 6	CON of Goselin, G. Storer, R. LaColla, A. Sommadossi, J.-P.	11/005,446	12/6/04 " and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999053	11874-053-599	1017 US CON 7	CON of Goselin, G. Storer, R. LaColla, A. Sommadossi, J.-P.	11/005,472	12/6/04 " and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-999054	11874-054-599	1017 US CON 8	CON of Goselin, G. Storer, R. LaColla, A. Sommadossi, J.-P.	11/005,444	12/6/04 " and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections

Date Inv/CAM	Bucket No.	Item No. Ref. No.	Type Related	Investor	Serial No.	Filed	Title
4/17451-880035	11874-055-888	1018 US PROV		Sauer, R. Gossein, G. Summadowsi, J.-P. Mauras, A. LeCalle, P.	6/09/2002 60392,350	6/28/02	Modified 2' and 3' Nucleotide Products for Treating Hepatitis C Virus
4/17451-890025	11874-055-599	1018 US PROV		Sauer, R. Gossein, G. Summadowsi, J.-P. LeCalle, P.	10/06/2002 11874-055-888 11874-130-888	6/27/03	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
4/17451-890056	11874-056-999	1018 US CON 1	CON of 11874-055-599	Sauer, R. LeCalle, P. Gossein, G. Summadowsi, J.-P.	11/06/2002 11874-055-599	12/6/04	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
4/17451-890057	11874-057-599	1018 US CON 2	CON of 11874-055-599	Sauer, R. LeCalle, P. Gossein, G. Summadowsi, J.-P.	11/06/2002 11874-055-599	12/6/04	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
4/17451-890058	11874-058-599	1018 US CON 3	CON of 11874-055-599	Sauer, R. LeCalle, P. Gossein, G. Summadowsi, J.-P.	11/06/2002 11874-055-599	12/6/04	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
4/17451-990059	11874-059-599	1018 US CON 4	CON of 11874-055-599	Sauer, R. LeCalle, P. Gossein, G. Summadowsi, J.-P.	11/06/2002 11874-055-599	12/6/04	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
4/17451-990060	11874-060-599	1018 US CON 5	CON of 11874-055-599	Sauer, R. LeCalle, P. Gossein, G. Summadowsi, J.-P.	11/06/2002 11874-055-599	12/6/04	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
4/17451-990061	11874-061-599	1018 US CON 6	CON of 11874-055-599	Sauer, R. LeCalle, P. Gossein, G. Summadowsi, J.-P.	11/06/2002 11874-055-599	12/6/04	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections
4/17451-990062	11874-062-599	1018 US CON 7	CON of 11874-055-599	Sauer, R. LeCalle, P. Gossein, G. Summadowsi, J.-P.	11/06/2002 11874-055-599	12/6/04	Modified 2' and 3' Nucleotide Products for Treating Flaviviridae Infections

Joint Dkt. No./CAM	Document No.	Month Ref. No.	Year Released	Inventor	Serial No.	Filed	Title
417451-996263	11874-063-999	1018 US	CON 8	CON of 11874-055-999	LaCola, P. Sheer, R. Crescenzi, G. Sommadossi, J.-P.	11/005,469	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-99190	11874-190-999	1018 US	DIV	DIV of 11874- 055-999	LaCola, P. Sheer, R. Crescenzi, G. Sommadossi, J.-P.	12/131,868	Modified 2' and 3' Nucleotide Prodrugs for Treating Flaviviridae Infections
417451-992026	11874-026-999	1031 US		11874-016-888 11874-130-888	Sommadossi, J.-P. La Cola, P. Crescenzi, G.	10/607,909	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cysteine for Treatment of Flaviviridae Infections
417451-990866	11874-086-999	1031 US	CON 1	CON of 11874-026-999	Sommadossi, J.-P. La Cola, P. Crescenzi, G.	11/516,928	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cysteine for Treatment of Flaviviridae Infections
417451-982077	11874-077-888	1040 US	PROV		Crescenzi, G. Setta, F. LaCola, P. Sheer, R. Duban, D. Lepo, F.	6/023,182	5'-Az-7-Deazguanine Derivatives for Treating Flaviviridae
417451-990277	11874-077-999	1040 US		11874-077-888	Crescenzi, G. Setta, F. LaCola, P. Sheer, R. Duban, D. Lepo, F.	11/166,498	5'-Az-7-Deazguanine Derivatives for Treating Flaviviridae
						6/23/2005	